Windtree Therapeutics, Inc. (WINT)
WINT moved a median of -1.40% 30 minutes after news, and -2.91% by the close. How WINT actually reacts to news — the realized, point-in-time move the market made, measured across 207 labeled events over the last three years with zero look-ahead.
WINT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.28% | 35% | 201 |
| 30-min | -1.40% | 27% | 203 |
| 60-min | -2.32% | 30% | 205 |
| to close | -2.91% | 29% | 202 |
| Middle 50% of WINT reactions | -4.93% to +0.29% |
|---|---|
| Median reaction (30-min) | -1.40% |
| Measured reactions | 207 |
Half of all Windtree Therapeutics, Inc. news events land between -4.93% and +0.29% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when WINT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to WINT's baseline. Nothing else.
Recent WINT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K WINDTREE THERAPEUTICS For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form NT 10-K WINDTREE THERAPEUTICS For: Dec 31 | SEC filing · Form NT | SEC EDGAR | — | -16.00% | |
| CommLoan Achieves Nationwide Regulatory Approval Across All 50 States | Press release | PR Newswire | +119.56% | +84.24% | |
| Form 8-K WINDTREE THERAPEUTICS For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +11.90% | |
| Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates | Press release | GlobeNewswire | -8.75% | -10.00% | |
| Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space | Press release | GlobeNewswire | +15.00% | +12.17% | |
| Form 8-K WINDTREE THERAPEUTICS For: Nov 25 | SEC filing · Form 8-K | SEC EDGAR | +15.00% | +12.17% | |
| Form 10-Q WINDTREE THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +9.90% | +0.80% | |
| Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee | Press release | GlobeNewswire | +3.50% | +0.00% | |
| Form NT 10-Q WINDTREE THERAPEUTICS For: Sep 30 | SEC filing · Form NT | SEC EDGAR | +3.50% | +0.00% | |
| Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate | Press release | GlobeNewswire | +0.00% | +4.67% | |
| Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company | Press release | GlobeNewswire | +23.55% | — | |
| Form S-1 WINDTREE THERAPEUTICS | SEC filing · Form S-1 | SEC EDGAR | -5.67% | -4.96% | |
| Form 8-K WINDTREE THERAPEUTICS For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | +6.22% | |
| Form 8-K WINDTREE THERAPEUTICS For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | — | +0.03% | |
| Form 8-K WINDTREE THERAPEUTICS For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +1.37% | -8.22% | |
| Form 8-K WINDTREE THERAPEUTICS For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +4.67% | +22.54% | |
| Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting | Press release | GlobeNewswire | -0.61% | -29.76% | |
| Form 8-K WINDTREE THERAPEUTICS For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -23.81% | -76.44% | |
| Form 10-Q WINDTREE THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.96% | -77.10% | |
| Form NT 10-Q WINDTREE THERAPEUTICS For: Jun 30 | SEC filing · Form NT | SEC EDGAR | +0.72% | +0.43% | |
| Form ARS WINDTREE THERAPEUTICS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.07% | — | |
| Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 | Press release | GlobeNewswire | -1.78% | -0.76% | |
| Form 8-K WINDTREE THERAPEUTICS For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -1.78% | -0.76% | |
| Form DEF 14A WINDTREE THERAPEUTICS For: Aug 28 | SEC filing · Form DEF | SEC EDGAR | -1.78% | -0.76% | |
| Form 8-K WINDTREE THERAPEUTICS For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -6.84% | |
| Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients | Press release | GlobeNewswire | +0.67% | -6.84% | |
| Form 8-K WINDTREE THERAPEUTICS For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -6.84% | |
| Form PRE 14A WINDTREE THERAPEUTICS For: Aug 28 | SEC filing · Form PRE | SEC EDGAR | +0.84% | -2.51% | |
| Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption | Press release | GlobeNewswire | +0.03% | — | |
| Form 8-K WINDTREE THERAPEUTICS For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | -6.86% | -12.82% | |
| Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy | Press release | GlobeNewswire | -6.86% | -12.82% | |
| Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services | Press release | GlobeNewswire | +0.80% | -3.85% | |
| Form 8-K WINDTREE THERAPEUTICS For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +25.04% | -22.79% | |
| Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions | Press release | GlobeNewswire | -10.74% | -11.77% | |
| Form EFFECT WINDTREE THERAPEUTICS | SEC filing · Form EFFECT | SEC EDGAR | -11.69% | -15.96% | |
| Form S-1/A WINDTREE THERAPEUTICS | SEC filing · Form S-1 | SEC EDGAR | +0.30% | -3.27% | |
| Form S-1/A WINDTREE THERAPEUTICS | SEC filing · Form S-1 | SEC EDGAR | +0.01% | +12.25% | |
| Form 8-K WINDTREE THERAPEUTICS For: Jun 27 | SEC filing · Form 8-K | SEC EDGAR | — | +0.00% | |
| Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure | Press release | GlobeNewswire | +5.95% | -9.94% | |
| Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis | Press release | GlobeNewswire | -1.74% | +12.20% | |
| Form 8-K WINDTREE THERAPEUTICS For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | +12.20% | |
| Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel | Press release | GlobeNewswire | -2.82% | -0.07% | |
| Form 8-K WINDTREE THERAPEUTICS For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | -5.82% | -23.14% | |
| Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study | Press release | GlobeNewswire | -3.12% | +2.86% | |
| Form 8-K WINDTREE THERAPEUTICS For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | -0.03% | |
| Windtree Receives Offer for Its Preclinical Oncology Drug Candidate | Press release | GlobeNewswire | -10.83% | -10.85% | |
| Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business | Press release | GlobeNewswire | -4.71% | -5.89% | |
| Windtree Announces Plan for Cryptocurrency Treasury Policy | Press release | GlobeNewswire | -0.99% | -6.96% | |
| Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 | Press release | GlobeNewswire | -1.12% | -2.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the WINT section they belong to.
Where else WINT is measured.
WINT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | 208 | -0.32% | 48% |
| Journey Medical Corporation (DERM) | 208 | 0.00% | 50% |
| Cronos Group Inc (CRON_TSE) | 206 | +0.15% | 50% |
| Pediatrix Medical Group, Inc. (MD) | 206 | +0.02% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Windtree Therapeutics, Inc.'s median reaction calculated?
Every labeled WINT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 207 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 27% of WINT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does WINT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.